Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Key facts

Sponsor

International Vaccine Institute

Principal Investigator

Maria Rosario Capeding, MD

Research Institution for Tropical Medicine

Intervention

Vi-DT(biological)

Enrollment

144 target

Eligibility

2-45 years · All sexes

Timeline

2016 – 2017

Collaborators

SK Chemicals Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Typhoid

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950
  Induction of Gut Permeability by an Oral Vaccine
  USDA, Western Human Nutrition Research Center
• ACTIVE NOT RECRUITINGPHASE3NCT03299426
  Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
  University of Maryland, Baltimore
• ACTIVE NOT RECRUITINGPHASE4NCT03970304
  CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults
  University of Maryland, Baltimore

See all trials for Typhoid →